Laekna, Inc. (HKG:2105)
Hong Kong · Delayed Price · Currency is HKD 6.02
-0.29 (-4.52%)
Sep 11, 2026, 4:08 PM HKT
Laekna Revenue
Laekna had revenue of 150.28M CNY in the half year ending June 30, 2026, with 36,914.04% growth. This brings the company's revenue in the last twelve months to 257.00M, up 6,163.61% year-over-year. In the year 2025, Laekna had annual revenue of 106.72M.
Revenue (ttm)
257.00M CNY
Revenue Growth
+6,163.61%
P/S Ratio
8.58
Revenue / Employee
3.10M CNY
Employees
83
Market Cap
2.55B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.72M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 280.00K | 169.00K | 152.25% |
| Dec 31, 2021 | 111.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 2.20B |
| Frontage Holdings | 2.18B |
| Qyuns Therapeutics | 1.18B |
| Antengene Corporation | 652.54M |
| Medtide | 635.93M |
| BioDlink International Company | 582.45M |
| Mirxes Holding Company | 166.32M |
| HJ Science | 16.30M |
Laekna News
- 4 weeks ago - Laekna's LAE002 NDA Accepted In China For HR+/HER2- Breast Cancer - Nasdaq